

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: True Leaf Medicine International Ltd. (the “**Issuer**”).

Trading Symbol: MJ

Number of Outstanding Listed Securities: 97,954,521 common shares (plus 18,645,713 common shares reserved for issuance in the form of 10,820,713 warrants and 7,825,000 options)

Date: April 1, 2019

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

During the past month, the Issuer generally continued to market its pet products and to develop its pet products line in addition to construction on its cultivation facility in Lumby, British Columbia.

On March 6, 2019, the Issuer announced that the current phase of construction of the True Leaf Campus – the Issuer’s cannabis cultivation and production facility – is complete. The completed phase includes a two-storey, 18,000 square foot central hub for the initial grow area, laboratory services, whole-plant extraction, and the production of therapeutic cannabis products for pets and their owners. The Issuer continues to work through the Health Canada approval process to cultivate and produce cannabis for True Leaf products. Depending on Health Canada timelines, approval is expected mid to late 2019.

On March 7, 2019, the Issuer announced that it has retained Hillcrest Merchant Partners Inc. (“**Hillcrest**”) as the Issuer’s Canadian capital markets advisor. Hillcrest provides advisory services, including introducing its clients to prospective investors, capital structuring, investor presentation and financial modelling preparation, strategic financing alternatives and positioning, and merger and acquisition advisory.

On March 13, 2019, the Issuer announced the launch of a new brand identity, redesigned logo and product innovations. The new brand identity features a logo with the True Leaf name in a simple, clear scripted typeface accented with an elegant leaf, highlighting the natural plant goodness of True Leaf’s products. The logo will be featured on all of the Issuer’s products, uniting them under a single banner, and reflecting True Leaf’s emergence as a global leader in cannabis and hemp wellness for pets. The new brand and expanded product line will begin being rolled out in May 2019 to nearly 2,500 pet retail stores in North America, with Europe to follow towards the end of the Year. The new brand and expanded pet product line were developed in partnership with Dossier Creative.

On March 15, 2019, the Issuer announced that it retained KCSA Strategic Communications (“**KCSA**”), a leading New York-based communications firm, to support the Issuer’s investor relations efforts in the United States. KCSA will employ a

comprehensive communications program designed to increase awareness of True Leaf across the investment community.

Also, on March 15, 2019, the Issuer announced that the market conditions had triggered the acceleration of the expiry of 871,795 warrants issued May 29, 2017 with an amended exercise price of \$0.355 per common share and 1,861,432 warrants issued June 12, 2017 with an amended exercise price of \$0.355 per common share (the “Warrants”). Under the terms of the Warrants, if for any 10 consecutive trading days the closing price of the Issuer’s common shares on the Canadian Securities Exchange exceeds \$0.44375, then the term of the Warrants will be reduced to 30 days commencing seven days from the end of such 10-day consecutive trading day period. On March 14, 2019, the closing price of the common shares exceeded \$0.44375 for 10 consecutive trading days. Accordingly, the expiry date for the Warrants is now April 21, 2019. Any warrants unexercised as of the new expiry date will be void and of no effect whatsoever. The Issuer’s warrants issued on May 29, 2017 and June 12, 2017 with an exercise price of \$0.45 per common share that are not subject to the recent repricing (warrant holders who did not elect to sign the Warrant Amending Agreement) will not be affected by the accelerated expiry date.

On March 20, 2019, the Issuer announced that it has expanded its total retail distribution to 3,500 stores worldwide with the addition of Pet Planet as a North American retail partner.

On March 22, 2019, the Issuer announced that it wished to clarify its news release dated March 15, 2019, at the request of IIROC, with respect to its engagement of KCSA. Specifically, the Issuer wished to clarify that for investor relations efforts provided in the United States, KCSA will receive USD\$8,000 per month. The term of the engagement will initially be two months and then ongoing on a month-to-month basis. The Issuer has the right to terminate the relationship on 30 days’ notice.

2. Provide a general overview and discussion of the activities of management.

Please see Item 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Please see Item 1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Please see Item 1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

Please see Item 1 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Please see Item 1 above.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Stock Options	1,675,000	March 6, 2019: 1,675,000 incentive stock options granted to various consultants, employees, and directors at an exercise price of \$0.56 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Common Shares	400,000	March 7, 2019: 400,000 warrants exercised at \$0.355 per common share.	Gross proceeds of \$142,000 for general working capital
Common Shares	90,000	March 12, 2019: 90,000 warrants exercised at \$0.355 per common share.	Gross proceeds of \$31,950 for general working capital
Common Shares	380,000	March 15, 2019: 380,000 warrants exercised at \$0.355 per common share.	Gross proceeds of \$134,900 for general working capital
Stock Options	750,000	March 21, 2019: 750,000 incentive stock options granted to an employee at an exercise price of \$0.61 per common share for a maximum period of 5 years (or earlier in accordance with the Issuer's stock option plan)	Not applicable
Common Shares	171,667	March 25, 2019: 171,667 warrants exercised at \$0.355 per common share.	Gross proceeds of \$60,941.79 for general working capital
Common Shares	500,000	March 27, 2019: 500,000 common shares issued at a deemed price of \$0.55 per share pursuant to the terms of consultant and employment agreements	Not applicable
Common Shares	26,650	March 29, 2019: 26,2650 warrants exercised at \$0.355 per common share.	Gross proceeds of \$9,460.75 for general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On June 20, 2018, the Government of Canada held the final vote on Bill C-45, the Cannabis Act, in the Senate. The Cannabis Act passed in the Senate and received Royal Assent on June 21, 2018. The Cannabis Act came into force on October 17, 2018, recreational cannabis is now available to legal adults (aged 18 or 19 depending on the province or territory) for purchase, growth, or use in limited quantities.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 1, 2019.

Darcy Bomford
Name of Director or Senior Officer

"Darcy Bomford"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer True Leaf Medicine International Ltd.	For Month End March 2019	Date of Report YY/MM/DD 19/04/01
Issuer Address 100 Kalamalka Lake Road, Unit 32		
City/Province/Postal Code Vernon, British Columbia V1T 9G1	Issuer Fax No. N/A	Issuer Telephone No. 778.475.5323
Contact Name Darcy Bomford	Contact Position President, CEO, and Director	Contact Telephone No. 778.475.5323
Contact Email Address Darcy@trueleaf.com	Web Site Address www.trueleaf.com	